Demonstrating Potential of Proprietary Enzyme-Based Technology to Improve Nutrition in Patients with Exocrine Pancreatic Insufficiency
NEWTON, Mass. – October 23, 2014 – Alcresta®, a specialty pharmaceutical company focused on improving patient nutrition by developing innovative enzyme-based products, today announced that two posters highlighting the company’s proprietary point-of-care products and their benefit to patients suffering from exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis (CF) and other serious diseases were presented at the 28th Annual North American Cystic Fibrosis Conference (NACFC). EPI is associated with reduced absorption of critical nutrients and calories, which can lead to poor growth and development, inability to maintain or increase weight, inflammation, and impaired cognitive and cardiovascular development and function.
“The data presented at NACFC highlight the potential of our enzyme-based technology to support and improve nutrition in patients battling CF or other acute or chronic diseases that cause pancreatic insufficiency or malabsorption,” said John Tucker, chief executive officer of Alcresta. “This growing data set strengthens the value our enzyme-based point-of-care platform may provide patients. We continue to prepare for the launch of our lead product, with the hope of making it available to patients in 2015.”
The abstract titled “Increased Total Fat and Long Chain Polyunsaturated Fatty Acid Absorption in Pigs with Exocrine Pancreatic Insufficiency Fed a Formula Pre-hydrolyzed with a Novel Point-of- Care Lipase (ALCT-460)” presented preclinical data demonstrating that Alcresta’s proprietary enzyme-based technology, iLipase®, is safe, well tolerated, and significantly enhanced absorption of fats critical for growth and development, and increased blood and tissue levels of long chain poly-unsaturated fatty acids, including docosahexaenoic acid (DHA) and arachidonic acid (AA). The authors concluded that Alcresta’s technology represents an important advancement for CF patients in need of improved digestion, fat absorption and additional calories from liquid nutritional feedings.
Patients with CF have difficulty managing weight, and up to 20 percent of patients rely on enteral, or tube, feedings to meet their dietary requirements. In the abstract titled “Novel Point of Care Lipase Device (EFICTM) to Pre-Hydrolyze Fats and Increase Absorption for Enteral Feeding,” the authors demonstrated that EFIC, a novel enzyme based enteral feeding in-line cartridge and Alcresta’s lead program, is able to effectively hydrolyze fats, including DHA and EPA, contained in common nutritional drinks used in tube feedings. The technology pre-digests fats into absorbable free fatty acids and monoglycerides, increasing caloric intake without impacting flow rate.
Alcresta is a specialty pharmaceutical company focused on improving patient nutrition by developing innovative enzyme-based products. The demand for high-value nutritional products is
increasing, driving the growth of a $40 billion global market. While there have been important recent advances in nutritional drinks and products, there remains a significant need for enzyme- based nutritional products that support healthier living, maximize nutrient and caloric absorption, and complement conventional medical care. Leveraging its existing proprietary platform of point- of-care nutritional products, Alcresta has developed a lead product designed to improve the digestion and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). The importance of long-chain polyunsaturated fatty acids like omega-3 is well documented across the full spectrum of patient care from infants to adults and individuals battling acute conditions or chronic diseases. The company’s platform is supported by the Alcresta team’s extensive experience in pharmaceutical and nutritional product development. Based in Newton, Mass., the company is backed by top-tier venture investors Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures. For more information, please visit www.alcresta.com.
About the NACFC
The North American Cystic Fibrosis Conference serves as a collaborative forum to advance research for the treatment and cure of CF, and is an ideal opportunity to receive state-of-the-art continuing medical education and learn about the latest products and services in CF care. The educational elements of the meeting program are targeted to physicians, nurses, research scientists, respiratory therapists, physical therapists, nutritionists, social workers, and pharmacists to share the latest research and advances in CF. The meeting is held over three days with more than 60 concurrent sessions.
Robert Gallotto, President Alcresta, Inc. 617-916-1207
Pure Communications Inc. 973-271-6085